ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2249

Evaluation of Rheumatoid Arthritis Patients’ Preferences Using Discrete Choice Experiment

Aniket Kawatkar1, 1Kaiser Permanente Southern California, Pasadena, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: discrete choice experiment, patient outcomes and shared decision making, patient preferences, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) exerts multifaceted burden through medical expenditures, productivity losses, disability, and intangible costs of pain, fatigue, and loss of functional capacity. Patient preference measures how they value a health outcome and it can be elicited by the trade-offs they place on different levels of the health outcomes. The study objective was to evaluate patients’ preferences for pain/fatigue, functional capacity, disability and joint replacement surgery, employment losses, and out-of-pocket cost using a discrete choice experiment (DCE).

Methods: A DCE was conducted in a prospective cohort of adult (18+ years) RA patients on methotrexate treatment, identified from the member population of Kaiser Permanente Southern California health plan. The web-based DCE survey varied the following 5 conjoint attributes with 3 levels in each: (1) Joint pain, swelling and tiredness (None, Moderate, Severe) (2) Limitations in daily activities (None, Moderate, Severe) (3) Chances of being disabled and require joint replacement surgery (Low (5%); Medium (40%),  High (90%)) (4) Number of days missed work due to RA (1 day/month, 8 days/month, 24 days/month) (5) Out of pocket treatment cost ($20/Month, $500/Month, $2,500/Month). After initial pilot testing, graphical representation of levels was used to convey magnitude to patients. The choice profiles for each respondent were randomly sampled from the full-choice design ensuring level balance and near-orthogonality within each respondent’s profile. After completing 2 training tasks (not analyzed), each respondent completed 12 random choice tasks that provided trade-offs to varying levels of the 5 outcomes. Hierarchical Bayesian models were used to evaluate individual patient preferences accounting for inter-patient heterogeneity.

Results: The DCE completion rate was 53% (237/448) and the mean age of the sample was 53 (±16) years with the majority (84%) of female. Of the 5 attributes, chance of disability and joint replacement surgery was tied with out-of-pocket treatment cost as the most important attributes (Table 1) and loss in functional capacity was deemed more important compared to missing work and pain/tiredness.  The average preference was 114 (95% CI 111-117) higher for low (5%) vs. high (90%) chance of being disabled and require joint replacement surgery (Table 2). In contrast, the average preference of moderate vs. no joint pain, swelling and tiredness was just one-unit difference (Table 2).

Conclusion: Treat-to-target approach based on swelling/tenderness/pain activity indices can be made more effective by shared decision making to incorporate patient preferences which value functional capacity and treatment cost higher. Better understanding of patient preferences can inform gaps in the existing evidence-base to inform practice guidelines.


Table 1

Table 1. Average Importance of Outcomes


Table 2

Table 2. Average Patient Preferences


Disclosure: A. Kawatkar, Medac Pharma, Inc., 2, Bristol-Myers Squibb, 2, Shire, 2, Novartis, 2.

To cite this abstract in AMA style:

Kawatkar A. Evaluation of Rheumatoid Arthritis Patients’ Preferences Using Discrete Choice Experiment [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-rheumatoid-arthritis-patients-preferences-using-discrete-choice-experiment/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-rheumatoid-arthritis-patients-preferences-using-discrete-choice-experiment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology